The impact of genotype on outcome in oligodendroglioma: Validation of the loss of chromosome arm 1p as an important factor in clinical decision making

Journal of Neurosurgery

Volumn 104, Issue 4, 2006, Pages 542-550

  Kanner, Andrew A ^b   Staugaitis, Susan M ^b   Castilla, Elias A ^b   Chernova, Olga ^b   Prayson, Richard A ^b   Vogelbaum, Michael A ^b   Stevens, Glen ^b   Peereboom, David ^b   Suh, John ^b   Lee, Shih Yuan ^b   Tubbs, Raymond R ^b   Barnett, Gene H ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b NONE

Author keywords

19q; 1p; Chromosomal analysis; Fluorescence in situ hybridization; Oligodendroglioma; Prognosis

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER GRADING; CHEMOSENSITIVITY; CHROMOSOME ARM; CHROMOSOME ARM 19Q; CHROMOSOME ARM 1P; CLINICAL DECISION MAKING; CONTROLLED STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; GENETIC ANALYSIS; GENOTYPE; GLIOBLASTOMA; GLIOMA; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OLIGODENDROGLIOMA; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; SCHOOL CHILD; SURVIVAL TIME; VALIDATION STUDY;

ADOLESCENT; ADULT; AGED; BRAIN; CELL TRANSFORMATION, NEOPLASTIC; CHROMOSOMES, HUMAN, PAIR 1; CHROMOSOMES, HUMAN, PAIR 19; DECISION SUPPORT TECHNIQUES; FEMALE; GENOTYPE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LOSS OF HETEROZYGOSITY; MALE; MIDDLE AGED; OLIGODENDROGLIOMA; PROGNOSIS; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; SUPRATENTORIAL NEOPLASMS; SURVIVAL RATE;

EID: 33645544191     PISSN: 00223085     EISSN: 00223085     Source Type: Journal    
DOI: 10.3171/jns.2006.104.4.542     Document Type: Article

References (42)

1. Armstrong CL, Hunter JV, Ledakis GE, Cohen B, Tallent EM, Goldstein BH, et al: Late cognitive and radiographic changes related to radiotherapy: initial prospective findings. Neurology 59:40-48, 2002
2. Bauman GS, Ino Y, Ueki K, Zlatescu MC, Fisher BJ, Macdonald DR, et al: Allelic loss of chromosome 1p and radiotherapy plus chemotherapy in patients with oligodendrogliomas. Int J Radiat Oncol Biol Phys 48:825-830, 2000
3. Bello MJ, Vaquero J, de Campos JM, Kusak ME, Sarasa JL, Saez-Castresana J, et al: Molecular analysis of chromosome 1 abnormalities in human gliomas reveals frequent loss of 1p in oligodendroglial tumors. Int J Cancer 57:172-175, 1994
4. Bigner SH, Matthews MR, Rasheed BK, Wiltshire RN, Friedman HS, Friedman AH, et al: Molecular genetic aspects of oligodendrogliomas including analysis by comparative genomic hybridization. Am J Pathol 155:375-386, 1999
5. Cairncross JG, Ueki K, Zlatescu MC, Lisle DK, Finkelstein DM, Hammond RR, et al: Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 90:1473-1479, 1998
6. Castilla EA, Prayson RA, Kanner AA, Rybicki LA, Tubbs RR, Vogelbaum MA, et al: Cyclooxygenase-2 in oligodendroglial neoplasms. Cancer 98:1465-1472, 2003
7. Celli P, Nofrone I, Palma L, Cantore G, Fortuna A: Cerebral oligodendroglioma: prognostic factors and life history. Neurosurgery 35:1018-1035, 1994
8. Chahlavi A, Kanner A, Peereboom D, Staugaitis SM, Elson P, Barnett G: Impact of chromosome 1p status in response of oligodendroglioma to temozolomide: preliminary results. J Neurooncol 61:267-273, 2003
9. Coons SW, Johnson PC, Scheithauer BW, Yates AJ, Pearl DK: Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas. Cancer 79:1381-1393, 1997
10. Fallon KB, Palmer CA, Roth KA, Nabors LB, Wang W, Carpenter M, et al: Prognostic value of 1p, 19q, 9p, 10q, and EGFRFISH analyses in recurrent oligodendrogliomas. J Neuropathol Exp Neurol 63:314-322, 2004
11. Fortin D, Cairncross GJ, Hammond RR: Oligodendroglioma: an appraisal of recent data pertaining to diagnosis and treatment. Neurosurgery 45:1279-1291, 1999
12. Gannett DE, Wisbeck WM, Silbergeld DL, Berger MS: The role of postoperative irradiation in the treatment of oligodendroglioma. Int J Radiat Oncol Biol Phys 30:567-573, 1994
13. Hartmann C, Mueller W, Lass U, Kamel-Reid S, von Deimling A: Molecular genetic analysis of oligodendroglial tumors. J Neuropathol Exp Neurol 64:10-14, 2005
14. Hercbergs AA, Goyal LK, Suh JH, Lee S, Reddy CA, Cohen BH, et al: Propylthiouracil-induced chemical hypothyroidism with high dose tamoxifen prolongs survival in recurrent high grade glioma: a Phase I/II study. Anticancer Res 23:617-626, 2003
15. Hoang-Xuan K, Capelle L, Kujas M, Taillibert S, Duffau H, Lejeune J, et al: Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions. J Clin Oncol 22:3133-3138, 2004
16. Ino Y, Betensky RA, Zlatescu MC, Sasaki H, Macdonald DR, Stemmer-Rachamimov AO, et al: Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis. Clin Cancer Res 7:839-845, 2001
17. Ino Y, Zlatescu MC, Sasaki H, Macdonald DR, Stemmer-Rachamimov AO, Jhung S, et al: Long survival and therapeutic responses in patients with histologically disparate high-grade gliomas demonstrating chromosome 1p loss. J Neurosurg 92:983-990, 2000
18. Karim AB, Afra D, Cornu P, Bleehan N, Schraub S, DeWitte O, et al: Randomized trial on the efficacy of radiotherapy for cerebral low-grade glioma in the adult: European Organization for Research and Treatment of Cancer Study 22845 with the Medical Research Council study BRO4: an interim analysis. Int J Radiat Oncol Biol Phys 52:316-324, 2002
19. Karim AB, Maat B, Hatlevoll R, Menten J, Rutten EH, Thomas DG, et al: A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844. Int J Radiat Oncol Biol Phys 36:549-556, 1996
20. Keles GE, Lamborn KR, Berger MS: Low-grade hemispheric gliomas in adults: a critical review of extent of resection as a factor influencing outcome. J Neurosurg 95:735-745, 2001
21. Kraus JA, Glesmann N, Beck M, Krex D, Klockgether T, Schackert G, et al: Molecular analysis of the PTEN, TP53 and CDKN2A tumor suppressor genes in long-term survivors of glioblastoma multiforme. J Neurooncol 48:89-94, 2000
22. Lindegaard KF, Mork SJ, Eide GE, Halvorsen TB, Hatlevoll R, Solgaard T, et al: Statistical analysis of clinicopathological features, radiotherapy, and survival in 170 cases of oligodendroglioma. J Neurosurg 67:224-230, 1987
23. Maintz D, Fiedler K, Koopmann J, Rollbrocker B, Nechev S, Lenartz D, et al: Molecular genetic evidence for subtypes of oligoastrocytomas. J Neuropathol Exp Neurol 56:1098-1104, 1997
24. McDonald JM, See SJ, Tremont IW, Colman H, Gilbert MR, Groves M, et al: The prognostic impact of histology and 1p/19q status in anaplastic oligodendroglial tumors. Cancer 104:1468-1477, 2005
25. Newcomb EW, Cohen H, Lee SR, Bhalla SK, Bloom J, Hayes RL, et al: Survival of patients with glioblastoma multiforme is not influenced by altered expression of p16, p53, EGFR, MDM2 or Bcl-2 genes. Brain Pathol 8:655-667, 1998
26. Paleologos NA, Cairncross JG: Treatment of oligodendroglioma: an update. Neurooncol 1:61-68, 1999
27. Plautz GE, Barnett GH, Miller DW, Cohen BH, Prayson RA, Krauss JC, et al: Systemic T cell adoptive immunotherapy of malignant gliomas. J Neurosurg 89:42-51, 1998
28. Plautz GE, Miller DW, Barnett GH, Stevens GH, Maffett S, Kim J, et al: T cell adoptive immunotherapy of newly diagnosed gliomas. Clin Cancer Res 6:2209-2218, 2000
29. Reifenberger G, Kros JM, Burger PC, Louis DN, Collins VP: Oligodendroglioma and anaplastic oligodendroglioma, in Kleihues P, Cavenee WK (eds): Pathology and Genetics of Tumours of the Nervous System. Lyon, France: IARC Press, 2000, pp 56-64
30. Reifenberger J, Reifenberger G, Liu L, James CD, Wechsler W, Collins VP: Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. Am J Pathol 145:1175-1190, 1994
31. Sasaki H, Zlatescu MC, Betensky RA, Johnk LB, Cutone AN, Cairncross JG, et al: Histopathological-molecular genetic correlations in referral pathologist-diagnosed low-grade "oligodendroglioma". J Neuropathol Exp Neurol 61:58-63, 2002
32. Schmidt MC, Antweiler S, Urban N, Mueller W, Kuklik A, Meyer-Puttlitz B, et al: Impact of genotype and morphology on the prognosis of glioblastoma. J Neuropathol Exp Neurol 61:321-328, 2002
33. Shaw EG, Scheithauer BW, O'Fallon JR, Tazelaar HD, Davis DH: Oligodendrogliomas: the Mayo Clinic experience. J Neurosurg 76:428-434, 1992
34. Smith JS, Alderete B, Minn Y, Borell TJ, Perry A, Mohapatra G, et al: Localization of common deletion regions on 1p and 19q in human gliomas and their association with histological subtype. Oncogene 18:4144-4152, 1999
35. Smith JS, Perry A, Borell TJ, Lee HK, O'Fallon J, Hosek SM, et al: Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol 18:636-645, 2000
36. Streffer J, Schabet M, Bamberg M, Grote EH, Meyermann R, Voigt K, et al: A role for preirradiation PCV chemotherapy for oligodendroglial brain tumors. J Neurol 247:297-302, 2000
37. Thiessen B, Maguire JA, McNeil K, Huntsman D, Martin MA, Horsman D: Loss of heterozygosity for loci on chromosome arms 1p and 10q in oligodendroglial tumors: relationship to outcome and chemosensitivity. J Neurooncol 64:271-278, 2003
38. Ueki K, Nishikawa R, Nakazato Y, Hirose T, Hirato J, Funada N, et al: Correlation of histology and molecular genetic analysis of 1p, 19q, 10q, TP53, EGFR, CDK4, and CDKN2A in 91 astrocytic and oligodendroglial tumors. Clin Cancer Res 8:196-201, 2002
39. van den Bent MJ, Keime-Guibert F, Brandes AA, Taphoorn MJ, Kros JM, Eskens FA, et al: Temozolomide chemotherapy in recurrent oligodendroglioma. Neurology 57:340-342, 2001
40. von Deimling A, Louis DN, Wiestler OD: Molecular pathways in the formation of gliomas. Glia 15:328-338, 1995
41. Walker C, du Plessis DG, Fildes D, Haylock B, Husband D, Jenkinson MD, et al: Correlation of molecular genetics with molecular and morphological imaging in gliomas with an oligodendroglial component. Clin Cancer Res 10:7182-7191, 2004
42. Zlatescu MC, TehraniYazdi A, Sasaki H, Megyesi JF, Betensky RA, Louis DN, et al: Tumor location and growth pattern correlate with genetic signature in oligodendroglial neoplasms. Cancer Res 61:6713-6715, 2001